Knowledge Library

Janus Kinases: Structural Biology Services

The inhibition of the JAK/STAT signaling pathway is a promising approach for the treatment of cancers and inflammatory diseases. To support drug discovery programs, we have established off-the-shelf crystallization systems to enable the determination of high-resolution X-ray crystal structures with a short turnaround time. Together with our protein production service and off-the-shelf biochemical and biophysical …Read More >

Resource Type: Presentation
Resource Topic: Biophysical Assays, Oncology, Structural Biology, X-ray Crystallography

VIEW

Radionuclide Drug Conjugates

Radiopharmaceuticals have proven to be effective agents since they can be successfully applied for both diagnostics and therapy. Radionuclide drug conjugates (RDCs) combine a radioactive compound, a tailored-targeting molecule for specific receptors enriched on diseased cells, and a linker for stable attachment, enabling more effective radiation delivery and significantly reducing side effects by attacking only …Read More >

Resource Type: Video
Resource Topic: in vivo Pharmacology, Oncology

VIEW

mRNA-Encoded Modulators Suppress Tumor Growth

Unlike conventional protein-targeted therapies, nucleic acid therapeutics have the potential for long-lasting effects and greater target specificity. WuXi AppTec provides a comprehensive platform to support the discovery of mRNA drugs.  Our services include mRNA design and production, assessment of mRNA delivery systems, in vitro evaluation, and determination of in vivo efficacy and biodistribution. At AACR …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Immunology, in vivo Pharmacology, Oligonucleotides, Oncology

VIEW

Cancer Pharmacology Services

WuXi Biology offers an integrated package of preclinical cancer pharmacology services for targeted oncology and immuno-oncology.  Our platform includes in vitro cell-free and cell-based assays, a comprehensive panel of in vivo tumor models, and multidisciplinary ex vivo PD analysis services. We have pioneered the development of over 1,500 PDX models across 30 cancer types, encompassing both …Read More >

Resource Type: Brochure
Resource Topic: Biomarkers, in vitro biology, in vivo Pharmacology, Oncology

VIEW

Clinical Drug Resistant PDX Models

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure.  The development of targeted therapies for overcoming drug resistance represents an unmet medical need. Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Oncology, Tumor Models

VIEW

OncoWuXi Express: Efficacy of DLL3 CAR-T in SHP-77 Tumor Models

OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models  Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our DLL3 CAR-T cell preparation and evaluation of their anti-tumor …Read More >

Resource Type: Article, Blog
Resource Topic: CAR-T Cell, Oncology, Tumor Models

VIEW

Combating Drug Resistance in Cancer Therapy

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. This resistance is inherent to the tumor cells themselves, as well as tied to factors within the tumor microenvironment (TME). To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of tumor resistance, WuXi Biology has …Read More >

Resource Type: Video
Resource Topic: Oncology, Tumor Models

VIEW

OncoWuXi Express: Paclitaxel-Induced Resistant Tumor Models

Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the newly established paclitaxel resistant HGC27 and HCC1806 tumor models. https://onco.wuxiapptec.com Paclitaxel, known for its …Read More >

Resource Type: Article, Blog
Resource Topic: Oncology, Tumor Models

VIEW

Recent Insights into Immuno-Oncology

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated through CAR-T, leading to the inhibition of CAR-T cell activity via the PD-1 pathway. At the 2024 Recent Insights into Immuno-Oncology Conference, WuXi AppTec presented a poster describing an engineered CAR-T therapy that targets mesothelin …Read More >

Resource Type: Latest Science, Poster
Resource Topic: CAR-T Cell, Oncology

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!